Advances in synthesis of pimavanserin / 国际药学研究杂志
Journal of International Pharmaceutical Research
;
(6): 688-691, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-845516
ABSTRACT
Pimavanserin(Nuplazid) is a drug of selective targeting 5-HT2A receptor, developed by Acadia Pharmaceuticals. In April 29, 2016, it was approved by FDA for the treatment of Parkinson’s disease (PD) patients experiencing mental symptoms such as hallucinations and delusions. In this paper, we summarize the synthetic methods of pimavanserin published in literature in recent years and their advantages and disadvantages.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Pharmaceutical Research
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS